These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 24695359)

  • 1. Structural determinants of the catalytic inhibition of human topoisomerase IIα by salicylate analogs and salicylate-based drugs.
    Bau JT; Kurz EU
    Biochem Pharmacol; 2014 Jun; 89(4):464-76. PubMed ID: 24695359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.
    Bau JT; Kang Z; Austin CA; Kurz EU
    Mol Pharmacol; 2014 Feb; 85(2):198-207. PubMed ID: 24220011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
    Bau JT; Kurz EU
    Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
    Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
    Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HMGB1 interacts with human topoisomerase IIalpha and stimulates its catalytic activity.
    Stros M; Bacíková A; Polanská E; Stokrová J; Strauss F
    Nucleic Acids Res; 2007; 35(15):5001-13. PubMed ID: 17636313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cysteine-reactive alkyl hydroquinone modifies topoisomerase IIα, enhances DNA breakage, and induces apoptosis in cancer cells.
    Lin TY; Huang CP; Au LC; Chang YW; Hu CY; Lin SB
    Chem Res Toxicol; 2012 Nov; 25(11):2340-51. PubMed ID: 23088786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
    Park SE; Chang IH; Jun KY; Lee E; Lee ES; Na Y; Kwon Y
    Eur J Med Chem; 2013 Nov; 69():139-45. PubMed ID: 24013413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
    Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
    Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.
    Shapiro AB; Austin CA
    Anal Biochem; 2014 Mar; 448():23-9. PubMed ID: 24309019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
    Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
    Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
    Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase IIα.
    Gui M; Shi DK; Huang M; Zhao Y; Sun QM; Zhang J; Chen Q; Feng JM; Liu CH; Li M; Li YX; Geng M; Ding J
    Invest New Drugs; 2011 Oct; 29(5):800-10. PubMed ID: 20336347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
    Qin Y; Meng L; Hu C; Duan W; Zuo Z; Lin L; Zhang X; Ding J
    Mol Cancer Ther; 2007 Sep; 6(9):2429-40. PubMed ID: 17876042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
    Liang H; Wu X; Yalowich JC; Hasinoff BB
    Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II.
    Li Y; Luan Y; Qi X; Li M; Gong L; Xue X; Wu X; Wu Y; Chen M; Xing G; Yao J; Ren J
    Toxicol Sci; 2010 Dec; 118(2):435-43. PubMed ID: 20855424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
    Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
    Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unprecedented citrinin trimer tricitinol B functions as a novel topoisomerase IIα inhibitor.
    Du L; Liu HC; Fu W; Li DH; Pan QM; Zhu TJ; Geng MY; Gu QQ
    J Med Chem; 2011 Aug; 54(16):5796-810. PubMed ID: 21761866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
    Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
    Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of drug-stimulated topoisomerase II-DNA cleavable complex formation in wild-type HL-60 cells treated with an intracellular calcium buffer is correlated with decreased cytotoxicity and site-specific hypophosphorylation of topoisomerase IIalpha.
    Aoyama M; Grabowski DR; Dubyak GR; Constantinou AI; Rybicki LA; Bukowski RM; Ganapathi MK; Hickson ID; Ganapathi R
    Biochem J; 1998 Dec; 336 ( Pt 3)(Pt 3):727-33. PubMed ID: 9841887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.